HomeHealthAustralian Scientists are testing targeted chemotherapy for lung cancer patients

Australian Scientists are testing targeted chemotherapy for lung cancer patients

Reader's Pick

Scientists are testing targeted chemotherapy for lung cancer patients, that can be inhaled instead of being injected or taken orally. According to pharmaceutical scientist Nazrul Islam, from Queensland University of Technology (QUT) in Australia, lung cancer is one of the deadliest and most common cancers.

“Drug delivery directly into the lungs via an inhaler is an efficient way to achieve local and systemic effects of medications,” Islam said.

“My research is concerned with dry powder inhalation using chitosan nanoparticles loaded with drugs that can reach the lower respiratory tract and from there diffuse into the bloodstream,” he said.

Chitosan is a natural polymer that is biodegradable and biocompatible. It is low toxicity and it can be bound with therapeutic drugs and made into nanoparticles.

- Advertisement -

“As yet, no studies have conclusively shown complete biodegradation or elimination of chitosan nanoparticles in lung tissue and my research is concerned with finding the form of chitosan that is able to biodegrade in the lungs’ unique tissues,”

Islam said that while many scientists were investigating the delivery of chemotherapy drugs via the lungs, none has exclusively looked at chitosan as a safe carrier for lung drug delivery.

Chitosan also has mucoadhesive properties, which means it sticks to the lining of the lung cells.

It has been found to improve the absorption of therapeutic agents by opening the junctions between cells of the lung lining to allow the drug to target cancer cells.

- Advertisement -

Islam said much research suggested chitosan-based nanoparticle drug delivery could be the way of the future to deliver drugs for many different conditions besides lung cancer.

“We need more research to understand the real-life degradation of chitosan, and identify degradation products and their possible toxicities in the body before we can conduct human trials,” he said.

“Targeted delivery of drugs increases the target tissues’ exposure to the drug while reducing exposure of healthy cells and organs to that drug, which means less toxicity and fewer side-effects,” he added.

Islam said much research suggested chitosan-based nanoparticle drug delivery could be the way of the future to deliver drugs for many different conditions besides lung cancer.

“We need more research to understand the real-life degradation of chitosan, and identify degradation products and their possible toxicities in the body before we can conduct human trials,” he said.

Subscribe to our Newsletters

We don’t spam! Read our privacy policy for more info.

- Advertisement -

Read latest Business News and Startup news on TechGraph. Watch live and latest news on TechGraph TV. Follow us on Facebook or follow us on Twitter and Instagram. Listen audio news from TechGraph Briefings on Spotify, Google Podcast, Amazon Music & on Apple Podcast.
 

Krishna Mali
Krishna Mali
Founder & Editor of TechGraph.

Latest News

Promoted Links

Related Stories

Paytm Payouts transfers Rs 1,500 crores

India-based e-wallet company, PayTM said, "Its Paytm Payouts has transferred ov...

Japan approves 26 trillion yen as economic stimulus package to combat overseas risks

Japan's cabinet approved an economic stimulus package worth 26 trillion yen ($2...

Sino-US trade war offers Europe’s chance to bank more Chinese reserves: Analysis

Should European countries want the euro to replace the dollar as the world's do...

Samsung Electronics asks its shareholders to use electronic voting for upcoming AGM

Technology giant Samsung Electronics has adopted electronic voting for the firs...

Rahul Gandhi hits on RCEP says, ‘Make in India’ has become ‘Buy from China’

Asserting that "Make in India" has become "Buy from China," Congress leader Rah...

Employees union seeks FIR against Jet Airways boss Naresh Goyal, Vinay Dube and on SBI Chairman

The employee union of Jet Airways, which is facing its worst crisis, Friday sou...

Rajesh Bysani joins Brainly as its new CPO

A New York headquarter peer-to-peer learning platform, Brainly has announced th...

NPCI’s new 1.1% interchange fee on UPI PPIs receives mixed reactions from industry experts

A move by the National Payments Corporation of India (NPCI) to charge an interc...

Interview: Muthoot Finance Dy MD Alexander George says, “Monthly customer transactions double to 8.25 lakh”

In an interview with TechGraph, Alexander George Muthoot - Deputy Managing Dire...

Passwordless authentication platform 1Kosmos sees significant growth in India

1Kosmos, a leading multi-factor authentication solution provider has reported a...